Comparative Effects of Valsartan and Enalapril on Cardiac Sympathetic Nerve Activity and Plasma Brain Natriuretic Peptide in Patients with Congestive Heart Failure

Overview

Journal Heart

Date 2005 Sep 15

PMID 16159967

Citations 16

Authors

S Kasama

T Toyama

T Hatori

H Sumino

H Kumakura

Y Takayama

S Ichikawa

T Suzuki

M Kurabayashi

Affiliations

Soon will be listed here.

Abstract

Objective: To evaluate the effects of valsartan on cardiac sympathetic nerve activity, plasma brain natriuretic peptide (BNP) concentration, cardiac function, and symptoms in patients with congestive heart failure (CHF) by comparison with those of enalapril.

Methods: 50 patients with CHF (left ventricular ejection fraction (LVEF) < 40%) were randomly assigned to valsartan (80 mg/day; n = 25) or enalapril (5 mg/day; n = 25). All patients were also treated with a loop diuretic. The delayed heart to mediastinum count (H/M) ratio, delayed total defect score (TDS), and washout rate were determined from (123)I-meta-iodobenzylguanidine (MIBG) images. Plasma BNP concentrations were measured before and after six months of treatment. The left ventricular end diastolic volume (LVEDV) and LVEF were also determined by echocardiography.

Results: In patients receiving valsartan, TDS decreased from a mean (SD) of 43 (8) to 39 (10) (p < 0.01), H/M ratio increased from 1.70 (0.17) to 1.78 (0.22) (p < 0.05), washout rate decreased from 46 (11)% to 41 (10)% (p < 0.05), and plasma BNP concentration decreased from 237 (180) pg/ml to 143 (93) pg/ml (p < 0.05). In addition, LVEDV decreased from 172 (42) ml to 151 (45) ml (p < 0.05) and LVEF increased from 31 (7)% to 39 (10)% (p < 0.001). However, these parameters did not change significantly in patients receiving enalapril.

Conclusion: Plasma BNP concentration and (123)I-MIBG scintigraphic and echocardiographic parameters improved significantly after six months of treatment with valsartan. These findings indicate that valsartan can improve cardiac sympathetic nerve activity and left ventricular performance in patients with CHF.

Citing Articles

Looking for the ideal medication for heart failure with reduced ejection fraction: a narrative review.

Pascual-Figal D, Bayes-Genis A Front Cardiovasc Med. 2024; 11:1439696.

PMID: 39314771 PMC: 11417622. DOI: 10.3389/fcvm.2024.1439696.

Endothelial, Vascular and Sympathetic Alterations as Therapeutic Targets in Chronic Heart Failure.

Quarti-Trevano F, DellOro R, Cuspidi C, Ambrosino P, Grassi G Biomedicines. 2023; 11(3).

PMID: 36979781 PMC: 10044749. DOI: 10.3390/biomedicines11030803.

Autonomic nervous system and cardiac neuro-signaling pathway modulation in cardiovascular disorders and Alzheimer's disease.

Elia A, Fossati S Front Physiol. 2023; 14:1060666.

PMID: 36798942 PMC: 9926972. DOI: 10.3389/fphys.2023.1060666.

I-mIBG: Simplicity and reproducibility.

Curl K, Hansen C J Nucl Cardiol. 2018; 26(5):1566-1568.

PMID: 29380284 DOI: 10.1007/s12350-018-1196-9.

Comparative effects of long-acting and short-acting loop diuretics on cardiac sympathetic nerve activity in patients with chronic heart failure.

Matsuo Y, Kasama S, Toyama T, Funada R, Takama N, Koitabashi N Open Heart. 2016; 3(1):e000276.

PMID: 26870386 PMC: 4746525. DOI: 10.1136/openhrt-2015-000276.

References

Kasama S, Toyama T, Kumakura H, Takayama Y, Ichikawa S, Suzuki T . Spironolactone improves cardiac sympathetic nerve activity and symptoms in patients with congestive heart failure. J Nucl Med. 2002; 43(10):1279-85. View

Shimizu T, Okamoto H, Chiba S, Matsui Y, Sugawara T, Onozuka H . Long-term combined therapy with an angiotensin type I receptor blocker and an angiotensin converting enzyme inhibitor prolongs survival in dilated cardiomyopathy. Jpn Heart J. 2002; 43(5):531-43. DOI: 10.1536/jhj.43.531. View

Kasama S, Toyama T, Kumakura H, Takayama Y, Ichikawa S, Suzuki T . Effect of spironolactone on cardiac sympathetic nerve activity and left ventricular remodeling in patients with dilated cardiomyopathy. J Am Coll Cardiol. 2003; 41(4):574-81. DOI: 10.1016/s0735-1097(02)02855-3. View

Kasama S, Toyama T, Kumakura H, Takayama Y, Ichikawa S, Suzuki T . Addition of valsartan to an angiotensin-converting enzyme inhibitor improves cardiac sympathetic nerve activity and left ventricular function in patients with congestive heart failure. J Nucl Med. 2003; 44(6):884-90. View

Ogita H, Shimonagata T, Fukunami M, Kumagai K, Yamada T, Asano Y . Prognostic significance of cardiac (123)I metaiodobenzylguanidine imaging for mortality and morbidity in patients with chronic heart failure: a prospective study. Heart. 2001; 86(6):656-60. PMC: 1730035. DOI: 10.1136/heart.86.6.656. View

Cohn J, Tognoni G . A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2002; 345(23):1667-75. DOI: 10.1056/NEJMoa010713. View

Cerqueira M, Weissman N, Dilsizian V, Jacobs A, Kaul S, Laskey W . Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation. 2002; 105(4):539-42. DOI: 10.1161/hc0402.102975. View

Kasama S, Toyama T, Hoshizaki H, Oshima S, Taniguchi K, Suzuki T . Dobutamine gated blood pool scintigraphy predicts the improvement of cardiac sympathetic nerve activity, cardiac function, and symptoms after treatment in patients with dilated cardiomyopathy. Chest. 2002; 122(2):542-8. DOI: 10.1378/chest.122.2.542. View

De Tommasi E, Iacoviello M, Romito R, Ceconi C, Guida P, Massari F . Comparison of the effect of valsartan and lisinopril on autonomic nervous system activity in chronic heart failure. Am Heart J. 2003; 146(5):E17. DOI: 10.1016/S0002-8703(03)00366-1. View

10.

Latini R, Masson S, Anand I, Salio M, Hester A, Judd D . The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT. Eur Heart J. 2004; 25(4):292-9. DOI: 10.1016/j.ehj.2003.10.030. View

11.

Kasama S, Toyama T, Kumakura H, Takayama Y, Ishikawa T, Ichikawa S . Effects of intravenous atrial natriuretic peptide on cardiac sympathetic nerve activity in patients with decompensated congestive heart failure. J Nucl Med. 2004; 45(7):1108-13. View

12.

Hughes J, Roth R . Evidence that angiotensin enhances transmitter release during sympathetic nerve stimulation. Br J Pharmacol. 1971; 41(2):239-55. PMC: 1703258. DOI: 10.1111/j.1476-5381.1971.tb08025.x. View

13.

CURTISS C, Cohn J, VROBEL T, Franciosa J . Role of the renin-angiotensin system in the systemic vasoconstriction of chronic congestive heart failure. Circulation. 1978; 58(5):763-70. DOI: 10.1161/01.cir.58.5.763. View

14.

Antonaccio M, KERWIN L . Evidence for prejunctional inhibition of norepinephrine release by captopril in spontaneously hypertensive rats. Eur J Pharmacol. 1980; 68(2):209-12. DOI: 10.1016/0014-2999(80)90325-8. View

15.

. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987; 316(23):1429-35. DOI: 10.1056/NEJM198706043162301. View

16.

Henderson E, Kahn J, Corbett J, Jansen D, Pippin J, Kulkarni P . Abnormal I-123 metaiodobenzylguanidine myocardial washout and distribution may reflect myocardial adrenergic derangement in patients with congestive cardiomyopathy. Circulation. 1988; 78(5 Pt 1):1192-9. DOI: 10.1161/01.cir.78.5.1192. View

17.

Urata H, Healy B, Stewart R, BUMPUS F, Husain A . Angiotensin II-forming pathways in normal and failing human hearts. Circ Res. 1990; 66(4):883-90. DOI: 10.1161/01.res.66.4.883. View

18.

Francis G, Cohn J . Heart failure: mechanisms of cardiac and vascular dysfunction and the rationale for pharmacologic intervention. FASEB J. 1990; 4(13):3068-75. DOI: 10.1096/fasebj.4.13.2210153. View

19.

BUMPUS F, Catt K, Chiu A, deGasparo M, GOODFRIEND T, Husain A . Nomenclature for angiotensin receptors. A report of the Nomenclature Committee of the Council for High Blood Pressure Research. Hypertension. 1991; 17(5):720-1. DOI: 10.1161/01.hyp.17.5.720. View

20.

Yusuf S, Pitt B, Davis C, Hood W, Cohn J . Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991; 325(5):293-302. DOI: 10.1056/NEJM199108013250501. View